Interní Med. 2010; 12(11): 565-569

Gliclazide MR and its effects in preventing the development of vascular complications in diabetes

MUDr.Marek Honka
Interní klinika FN Ostrava

The paper presents an overview of the research dealing with the effects of gliclazide MR in a number of aspects of the pathophysiology

of vascular changes in diabetes. The efficacy of this agent has been demonstrated by long-term use in the clinical practice; however,

gliclazide MR has certain exceptional pharmacological properties and haemovascular and antioxidative effects which distinguish it from

the other agents of the class of sulfonylurea derivatives. The development of vascular complications in diabetes is a complex process

involving a number of different but interrelated components, e.g. oxidative stress and endothelial dysfunction can be favourably affected

by treatment with gliclazide independently of improved diabetes compensation. In addition to the low potential for the development of

hypoglycaemias due to the favourable pharmacodynamic parameters of gliclazide MR, the positive cardiovascular outcomes reported

in clinical trials, particularly in the ADVANCE project, may be explained in this way.

Keywords: diabetes mellitus, gliclazide MR, oxidative stress, vascular complications

Published: December 1, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Honka M. Gliclazide MR and its effects in preventing the development of vascular complications in diabetes. Interní Med. 2010;12(11):565-569.
Download citation

References

  1. Francillard M, Frey N, Paraire M, et al. Pharmacokinetics of DIAMICRON modified release (MR) in 1007 type 2 diabetic patients. J Nutr Health Aging 2001; 5 (Special issue): 14.
  2. Guillausseau PJ, Greb WH. 24-hour glycemic profile in type 2 diabetic patients treated with gliclazide modified release once daily. Diabetes Metab 2001; 2: 133-137.
  3. Schernthaner G, Grimaldi A, Di Mario U. GUIDE (Glucose control in type 2 diabetes DIAMICRON MR versus glimEpiride) study. Eur J Clin Invest 2004; 34: 535-542. Go to original source... Go to PubMed...
  4. Satoh J, Takahashi K, Takizawa Y, et al. Secondary failure: comparison of period until treatment between diabetic patients treated with gliclazide and glibenclamide. Diabetes Res Clin Pract 2005; 70: 291-297. Go to original source... Go to PubMed...
  5. Hosker JP, Rudenski AS, Burnett MA, et al. Similar reduction of first- and second-phase ?-cell responses at three different glucose levels in type 2 diabetes and the effect of gliclazide therapy. Metabolism 1989; 38: 767-772. Go to original source... Go to PubMed...
  6. Gregorio F, Ambrosi F, Cristallini S, et al. Therapeutic concentrations of tolbutamide, glibenclamide, gliclazide and gliquidone at different glucose levels: in vitro effects on pancreatic ?-cell and ?-cell function. Diabetes Res Clin Practice 1992; 18: 197-206. Go to original source... Go to PubMed...
  7. Grram J. Metabolism 1988.
  8. Jennings P, Scott NA, Saniabadi AR, et al. Effects of gliclazide on platelet reactivity and free radicals in type II diabetic patients: clinical assessment. Metabolism 1992; 5: 36-39. Go to original source... Go to PubMed...
  9. Scott NA, Jennings PE, Brown J, et al. Gliclazide: a free radical scavenger. Eur J Pharmacol 1991; 208: 175-177. Go to original source... Go to PubMed...
  10. Kimoto K, Suzuki K, Kizaki T, et al. Gliclazide protects pancreatic ?-cells from damage by hydrogen peroxide. Biochem Biophys Res Commun 2003; 303: 112-119. Go to original source... Go to PubMed...
  11. Del Guerra S, Grupillo M, Masini M. Gliclazide protects human islet ?-cells from apoptosis induced by intermitent high glucose. Diabetes Metab Res Rev 2007; 23: 234-238. Go to original source... Go to PubMed...
  12. O´Brien RS, et al. In vitro and in vivo antioxidant properties of gliclazide. J Diabetes Complications 2000; 14: 201-206. Go to original source... Go to PubMed...
  13. Fava D, Cassone-Faldetta M, Laurenti O, et al. Gliclazide improves anti-oxidant status and nitric oxide-mediated vasodilation in Type 2 diabetes. Diabetic Med 2002; 19: 752-757. Go to original source... Go to PubMed...
  14. Škrha J. Oxidační stres a jeho význam ke komplikacím diabetu. Interní Med. 2010; 12(9): 414-418.
  15. Katakami N, Yamasaki Y, Hayaishi-Okano R, et al. Metformin of gliclazide, rather than glibenclamide, attenuate progression of carotid intima-media thickness in subjects with type 2 diabetes. Diabetologia 2004; 47: 1906-1913. Go to original source... Go to PubMed...
  16. ADVANCE Collaborative Group. Study Rationale and Design of ADVANCE: Action in Diabetes and Vascular Disease - Preterax and Diamicron MR controlled Evaluation. Diabetologia 2001; 44(9): 1018-1020. Go to original source...
  17. Honka M. Interní Med 2009.
  18. ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-2572. Go to original source... Go to PubMed...
  19. de Zeeuw D, Remuzzi G, Parving HH, et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 2004; 110: 921-927. Go to original source... Go to PubMed...
  20. The Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-2559. Go to original source... Go to PubMed...
  21. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with Type 2 diabetes. New. Engl. J. Med 2009; 360: 129-139. Go to original source... Go to PubMed...
  22. Johnsen SP, Monster TBM, Olsen ML, et al. Risk and ShortTerm Prognosis of Myocardial Infarction Among Users of Antidiabetic Drugs. Am J Ther 2006; 13: 134-140. Go to original source... Go to PubMed...




Internal Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.